Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling.

Karl S Lang, Panco Georgiev, Mike Recher, Alexander A Navarini, Andreas Bergthaler, Mathias Heikenwalder, Nicola L Harris, Tobias Junt, Bernhard Odermatt, Pierre-Alain Clavien, Hanspeter Pircher, Shizuo Akira, Hans Hengartner, Rolf M Zinkernagel
Author Information
  1. Karl S Lang: Institute of Experimental Immunology, University Hospital of Zurich, Zurich, Switzerland. karl.lang@usz.ch

Abstract

The liver is known to be a classical immunoprivileged site with a relatively high resistance against immune responses. Here we demonstrate that highly activated liver-specific effector CD8+ T cells alone were not sufficient to trigger immune destruction of the liver in mice. Only additional innate immune signals orchestrated by TLR3 provoked liver damage. While TLR3 activation did not directly alter liver-specific CD8+ T cell function, it induced IFN-alpha and TNF-alpha release. These cytokines generated expression of the chemokine CXCL9 in the liver, thereby enhancing CD8+ T cell infiltration and liver disease in mice. Thus, nonspecific activation of innate immunity can drastically enhance susceptibility to immune destruction of a solid organ.

References

Gastroenterology. 1995 Jun;108(6):1770-7 [PMID: 7768382]
J Exp Med. 1997 Feb 3;185(3):531-9 [PMID: 9053453]
Eur J Immunol. 2002 Dec;32(12):3628-37 [PMID: 12516551]
Am J Med. 2005 Aug;118(8):808-15 [PMID: 16084169]
Nat Med. 2005 Feb;11(2):138-45 [PMID: 15654326]
J Immunol. 2000 Sep 1;165(5):2415-22 [PMID: 10946266]
Eur J Immunol. 2005 Mar;35(3):738-45 [PMID: 15724249]
Lancet. 1989 Sep 16;2(8664):688 [PMID: 2570945]
Immunol Rev. 2000 Apr;174:260-79 [PMID: 10807522]
Lancet. 1995 Dec 16;346(8990):1603 [PMID: 7500754]
J Immunol. 2002 Jun 15;168(12):6032-40 [PMID: 12055211]
Nature. 2006 Mar 23;440(7083):540-4 [PMID: 16525420]
Diabetes. 2005 Sep;54(9):2549-56 [PMID: 16123342]
Nat Immunol. 2001 Feb;2(2):129-34 [PMID: 11175805]
Nat Immunol. 2004 Jul;5(7):730-7 [PMID: 15208624]
Hepatol Res. 2003 Mar;25(3):263-270 [PMID: 12697247]
Postgrad Med. 2003 Jul;114(1):79-82, 85-8 [PMID: 12875057]
Hepatology. 1999 Oct;30(4):851-6 [PMID: 10498633]
J Immunol. 2005 Jul 15;175(2):1047-55 [PMID: 16002705]
J Clin Invest. 2005 Oct;115(10):2904-13 [PMID: 16167085]
Nature. 1981 Aug 27;292(5826):840-2 [PMID: 7022223]
Nature. 2001 Oct 18;413(6857):732-8 [PMID: 11607032]
Science. 1994 Feb 4;263(5147):674-6 [PMID: 8303275]
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9237-42 [PMID: 11470918]
Eur J Immunol. 1998 Aug;28(8):2395-406 [PMID: 9710217]
Trends Mol Med. 2004 Aug;10(8):366-71 [PMID: 15310456]
Gastroenterology. 2003 Feb;124(2):352-60 [PMID: 12557141]
J Exp Med. 2005 Sep 5;202(5):637-50 [PMID: 16129706]
Nat Rev Immunol. 2004 Jul;4(7):499-511 [PMID: 15229469]
Immunol Res. 2005;33(3):195-212 [PMID: 16461998]
Nat Med. 1998 Jul;4(7):781-5 [PMID: 9662368]
Autoimmun Rev. 2004 Mar;3(3):207-14 [PMID: 15110233]
Immunol Rev. 1993 Jun;133:93-104 [PMID: 8225373]
J Exp Med. 2003 Jan 6;197(1):111-9 [PMID: 12515818]
Nat Med. 2002 Dec;8(12):1414-20 [PMID: 12415259]
Eur J Immunol. 2005 Mar;35(3):822-30 [PMID: 15724245]

MeSH Term

Adaptor Proteins, Signal Transducing
Adoptive Transfer
Animals
CD8-Positive T-Lymphocytes
Cytotoxicity, Immunologic
Humans
Interferon-alpha
L Cells
Liver
Liver Diseases
Mice
Mice, Knockout
Myeloid Differentiation Factor 88
Receptors, Tumor Necrosis Factor
Receptors, Tumor Necrosis Factor, Type I
Toll-Like Receptor 3
Tumor Necrosis Factor Decoy Receptors
Tumor Necrosis Factor-alpha

Chemicals

Adaptor Proteins, Signal Transducing
Interferon-alpha
MYD88 protein, human
Myd88 protein, mouse
Myeloid Differentiation Factor 88
Receptors, Tumor Necrosis Factor
Receptors, Tumor Necrosis Factor, Type I
Toll-Like Receptor 3
Tumor Necrosis Factor Decoy Receptors
Tumor Necrosis Factor-alpha
recombinant human tumor necrosis factor-binding protein-1

Word Cloud

Similar Articles

Cited By